Skip to main content
Terug
Watch Compare

NRX Pharmaceuticals, Inc.

Datakwaliteit: 100%
Ook genoteerd als NRXPW NASDAQ
NRXP
NASDAQ Manufacturing Chemicals
€ 2,56
▲ € 0,06 (2,40%)
6 months return
—
Momentum
Neutral
Net margin
-2336,49%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-2336,49%
Op. Margin-1324,41%

Veiligheid

Debt / Equity
N/A
Current Ratio0,15
Interest Coverage-24,18

Waardering

PE (TTM|NTM|2027)
-2,61 | 0,56 | 0,58
Onder sectorgemiddelde (-1,50)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -14,11 M

Price History

Financiële Trends

Koersdoel Analisten

4 analisten
Buy
+1384.4%
upside to target
Huidig
€ 2,56
Consensus Target
€ 38,00
€ 25,00
Laag
€ 48,00
Hoog
Vooruitzicht
Forward K/W
0,56
Forward WPA
€ 3,93
WPA Groei (sch.)
+2923,1%
Omzet Sch.
537,97 M

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,02 · Rev Est: 52,20 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,34 -€ 0,98 -€ 0,51 € 0,18 — —
Estimate -€ 0,25 -€ 0,23 -€ 0,02 -€ 0,08 -€ 0,02 € 0,02
Verrassing -36,00% -326,09% -2938,39% +329,13% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: -2336,49%
Revenue (TTM) 1,23 M Net Income (TTM) -28,62 M
ROE N/A ROA -783,95%
Gross Margin N/A Operating Margin -1324,41%
Net Margin -2336,49% Free Cash Flow (TTM) -14,11 M
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0,15
Debt / Equity N/A Current Ratio 0,15
Interest Coverage -24,18 Asset Turnover 0,34
Working Capital -18,56 M Tangible Book Value -23,22 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -2,61 · EV/EBITDA: N/A
P/E Ratio -2,61 Forward P/E 0,56
P/B Ratio N/A P/S Ratio 61,01
PEG Ratio N/A Forward PEG 0,00
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0,14 Fwd Earnings Yield 178,57%
FCF Yield -18,88%
Market Cap 74,73 M Enterprise Value 73,29 M

Per Share

EPS: N/A · FCF/Share: -0,43
EPS (Diluted TTM) N/A Revenue / Share 0,04
FCF / Share -0,43 OCF / Share -0,43
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 49,30% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 49,30%
SBC-Adj. FCF -14,91 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,23 M 0,0 — — —
Net Income -28,62 M -25,13 M -30,15 M -39,75 M -93,06 M
EPS (Diluted) — — — -0,60 -1,98
Gross Profit — — — — —
Operating Income -16,22 M -18,50 M -27,84 M -44,34 M -115,80 M
EBITDA — — — — —
R&D Expenses 3,78 M 6,20 M 13,37 M 17,03 M 20,26 M
SG&A Expenses 13,06 M — — — —
D&A 70.000,0 — — — —
Interest Expense 671.000,0 230.000,0 120.000,0 18.000,0 18.000,0
Income Tax 0,0 0,0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 12,96 M 3,65 M 7,32 M 25,82 M 32,73 M
Total Liabilities 28,89 M 26,87 M 19,05 M 18,41 M 11,92 M
Shareholders' Equity -15,94 M -23,22 M -11,73 M 7,41 M 20,81 M
Total Debt — — 9,16 M — —
Cash & Equivalents 7,80 M 1,44 M 4,60 M 20,05 M —
Current Assets 8,89 M 3,30 M 6,88 M 25,80 M 32,71 M
Current Liabilities 28,58 M 21,86 M 19,05 M 15,59 M 11,92 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -2,6 -1,5
P/B — 1,6
ROE % — -54,5
Net Margin % -2336,5 -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3

ETFs Holding This Stock
PSIL logo PSIL AdvisorShares Psychedelics ETF
6,59% weight